CN1786001A - 一种组成稳定的血卟啉衍生物及其制备方法和注射剂 - Google Patents
一种组成稳定的血卟啉衍生物及其制备方法和注射剂 Download PDFInfo
- Publication number
- CN1786001A CN1786001A CN 200510134599 CN200510134599A CN1786001A CN 1786001 A CN1786001 A CN 1786001A CN 200510134599 CN200510134599 CN 200510134599 CN 200510134599 A CN200510134599 A CN 200510134599A CN 1786001 A CN1786001 A CN 1786001A
- Authority
- CN
- China
- Prior art keywords
- precipitation
- solution
- haematoporphyrin
- injection liquid
- dissolved
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002347 injection Methods 0.000 title claims abstract description 35
- 239000007924 injection Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 239000003795 chemical substances by application Substances 0.000 title description 4
- 239000008280 blood Substances 0.000 title description 2
- 210000004369 blood Anatomy 0.000 title description 2
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical class CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 claims abstract description 47
- 150000004032 porphyrins Chemical class 0.000 claims abstract description 26
- 229920000642 polymer Polymers 0.000 claims abstract description 25
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 claims abstract description 18
- 229950003776 protoporphyrin Drugs 0.000 claims abstract description 18
- VFQCKFQOPJATGZ-WORMITQPSA-N 2-(2-deuterio-3-ethenyl-23H-porphyrin-21-yl)ethanol Chemical compound OCCN1C2=C(C(=C1C=C1C=CC(C=C3C=CC(=CC=4C=CC(=C2)N=4)N3)=N1)[2H])C=C VFQCKFQOPJATGZ-WORMITQPSA-N 0.000 claims abstract description 15
- 238000001556 precipitation Methods 0.000 claims description 71
- 239000000243 solution Substances 0.000 claims description 58
- KFKRXESVMDBTNQ-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-8,13-bis(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical compound N1C2=C(C)C(C(C)O)=C1C=C(N1)C(C)=C(C(O)C)C1=CC(C(C)=C1CCC(O)=O)=NC1=CC(C(CCC(O)=O)=C1C)=NC1=C2 KFKRXESVMDBTNQ-UHFFFAOYSA-N 0.000 claims description 56
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 42
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 33
- 239000007788 liquid Substances 0.000 claims description 25
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 24
- 238000005406 washing Methods 0.000 claims description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 23
- 238000001035 drying Methods 0.000 claims description 19
- 238000012546 transfer Methods 0.000 claims description 18
- 239000000047 product Substances 0.000 claims description 17
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 16
- 238000003745 diagnosis Methods 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 16
- 239000001632 sodium acetate Substances 0.000 claims description 16
- 235000017281 sodium acetate Nutrition 0.000 claims description 16
- -1 filters Substances 0.000 claims description 12
- 229910000042 hydrogen bromide Inorganic materials 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- 230000007935 neutral effect Effects 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 229960000583 acetic acid Drugs 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 239000012362 glacial acetic acid Substances 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 239000011259 mixed solution Substances 0.000 claims description 8
- 239000003708 ampul Substances 0.000 claims description 6
- 239000003914 blood derivative Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000011146 sterile filtration Methods 0.000 claims description 6
- 206010067193 Naevus flammeus Diseases 0.000 claims description 5
- 208000006787 Port-Wine Stain Diseases 0.000 claims description 5
- 208000002026 familial multiple nevi flammei Diseases 0.000 claims description 5
- 230000003902 lesion Effects 0.000 claims description 4
- 210000005075 mammary gland Anatomy 0.000 claims description 4
- 210000001989 nasopharynx Anatomy 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 3
- 210000000214 mouth Anatomy 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 claims description 2
- 210000000621 bronchi Anatomy 0.000 claims description 2
- 230000001079 digestive effect Effects 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 229960003569 hematoporphyrin Drugs 0.000 abstract description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- 238000004128 high performance liquid chromatography Methods 0.000 description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 238000000034 method Methods 0.000 description 12
- 229960004249 sodium acetate Drugs 0.000 description 12
- VAJVGAQAYOAJQI-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-3,8,13,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical compound N1C(C=C2C(C)=CC(N2)=CC=2C(=C(CCC(O)=O)C(=C3)N=2)C)=CC(C)=C1C=C1C(C)=C(CCC(O)=O)C3=N1 VAJVGAQAYOAJQI-UHFFFAOYSA-N 0.000 description 8
- 230000007170 pathology Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- 238000002428 photodynamic therapy Methods 0.000 description 7
- 239000013558 reference substance Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 239000012043 crude product Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- ZPEGJOPUKUPHNU-QOWOAITPSA-N C(=C)C=1C(=C2NC1C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2)[2H] Chemical compound C(=C)C=1C(=C2NC1C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2)[2H] ZPEGJOPUKUPHNU-QOWOAITPSA-N 0.000 description 4
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 201000005619 esophageal carcinoma Diseases 0.000 description 4
- 201000004637 gastric cardia carcinoma Diseases 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 201000000498 stomach carcinoma Diseases 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VFOJVHGXLJEETR-RWQOXAPSSA-N [2H]C1=C2NC(=C1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2.BrC(F)(F)F Chemical compound [2H]C1=C2NC(=C1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2.BrC(F)(F)F VFOJVHGXLJEETR-RWQOXAPSSA-N 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000010183 spectrum analysis Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 241000931526 Acer campestre Species 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical class COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical group C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- SLUMXGZMSGXWCJ-QOWOAITPSA-N OCCC=1C(=C2NC1C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2)[2H] Chemical compound OCCC=1C(=C2NC1C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2)[2H] SLUMXGZMSGXWCJ-QOWOAITPSA-N 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000005950 photosensitized reaction Methods 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- PHBMGNNAIBHRCI-QOWOAITPSA-N C(C)C=1C(=C2NC=1C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N=1)=C2)[2H] Chemical compound C(C)C=1C(=C2NC=1C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N=1)=C2)[2H] PHBMGNNAIBHRCI-QOWOAITPSA-N 0.000 description 1
- ZEBYNQXUMRQJEG-FCFVPJCTSA-N COC=1C(=C2N(C1C=C1C=C(C(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2)OC)CC)[2H] Chemical compound COC=1C(=C2N(C1C=C1C=C(C(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2)OC)CC)[2H] ZEBYNQXUMRQJEG-FCFVPJCTSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- LGDAGYXJBDILKZ-UHFFFAOYSA-N [2-methyl-1,1-dioxo-3-(pyridin-2-ylcarbamoyl)-1$l^{6},2-benzothiazin-4-yl] 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LGDAGYXJBDILKZ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- UXTMROKLAAOEQO-UHFFFAOYSA-N chloroform;ethanol Chemical compound CCO.ClC(Cl)Cl UXTMROKLAAOEQO-UHFFFAOYSA-N 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011121 hardwood Substances 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- WCYAALZQFZMMOM-UHFFFAOYSA-N methanol;sulfuric acid Chemical compound OC.OS(O)(=O)=O WCYAALZQFZMMOM-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
时间(月) | 批号 | pH值 | 血卟啉主组份比值 | 干燥失重% | 总卟啉% | 血卟啉% | 羟乙基-乙烯基次卟啉% | 原卟啉% | 卟啉聚合体% |
0 | 021201 | 4.2 | 1∶0.38 | 2.0 | 77.2 | 55.0 | 6.2 | 1.4 | 20.5 |
021202 | 4.2 | 1∶0.40 | 2.0 | 76.7 | 55.8 | 8.5 | 2.9 | 22.2 |
021203 | 4.4 | 1∶0.38 | 2.0 | 76.2 | 59.9 | 7.8 | 1.5 | 22.8 | |
3 | 021201 | 4.3 | 1∶0.38 | 2.1 | 77.0 | 54.7 | 6.4 | 1.8 | 20.8 |
021202 | 4.2 | 1∶0.41 | 2.5 | 76.5 | 53.8 | 8.9 | 2.6 | 22.1 | |
021203 | 4.3 | 1∶0.39 | 2.0 | 76.2 | 55.4 | 7.6 | 1.3 | 21.6 | |
6 | 021201 | 4.2 | 1∶0.40 | 2.1 | 77.1 | 53.0 | 6.5 | 1.7 | 21.2 |
021202 | 4.3 | 1∶0.40 | 2.6 | 76.3 | 57.9 | 8.3 | 3.2 | 23.2 | |
021203 | 4.3 | 1∶0.39 | 2.1 | 76.1 | 55.1 | 7.5 | 1.7 | 21.5 | |
9 | 021201 | 4.1 | 1∶0.40 | 2.2 | 76.9 | 53.1 | 6.3 | 1.5 | 21.2 |
021202 | 4.2 | 1∶0.42 | 2.6 | 76.4 | 57.6 | 8.3 | 2.6 | 24.2 | |
021203 | 4.5 | 1∶0.40 | 2.2 | 75.9 | 54.8 | 7.4 | 1.2 | 21.9 | |
12 | 021201 | 4.1 | 1∶0.40 | 2.2 | 77.0 | 52.9 | 6.4 | 1.5 | 21.2 |
021202 | 4.1 | 1∶0.40 | 2.6 | 76.3 | 57.3 | 8.6 | 2.3 | 22.9 | |
021203 | 4.4 | 1∶0.42 | 2.2 | 75.8 | 54.6 | 7.3 | 1.4 | 22.9 | |
18 | 021201 | 4.2 | 1∶0.42 | 2.3 | 76.9 | 52.8 | 6.0 | 1.3 | 22.2 |
021202 | 4.1 | 1∶0.40 | 2.6 | 76.2 | 57.3 | 7.9 | 2.4 | 22.9 | |
021203 | 4.3 | 1∶0.40 | 2.3 | 75.9 | 54.7 | 7.1 | 1.5 | 21.9 | |
24 | 021201 | 4.2 | 1∶0.40 | 2.3 | 76.8 | 52.8 | 6.1 | 1.2 | 21.1 |
021202 | 4.3 | 1∶0.40 | 2.7 | 76.0 | 57.0 | 7.3 | 2.5 | 22.8 | |
021203 | 4.4 | 1∶0.40 | 2.4 | 75.7 | 54.3 | 6.9 | 1.4 | 21.7 |
病种 | 市肿瘤所 | 协和 | 口腔 | 总医院 | 医科院 | 合计 |
浅表 | 37 | 37 | ||||
口腔颌面 | 40 | 40 | ||||
鼻咽 | 2 | 2 | ||||
肺 | 74 | 74 | ||||
乳腺 | 10 | 1 | 11 | |||
食管 | 60 | 1 | 61 | |||
贲门 | 128 | 128 | ||||
胃 | 37 | 37 | ||||
直肠 | 1 | 1 | ||||
膀胱 | 14 | 23 | 37 | |||
共计 | 226 | 61 | 40 | 74 | 27 | 428 |
诊断 | 例数 | 阳性 | 可疑 | 阴性 |
食管癌 | 28 | 25 | 2 | 1 |
贲门癌 | 56 | 53 | 2 | 1 |
胃癌 | 16 | 16 | 0 | 0 |
合计 | 100 | 94 | 4 | 2 |
诊断 | 例数 | CR | PR | MR | NR |
浅表 | 37 | 25 | 4 | 6 | 2 |
口腔颌面 | 40 | 33 | 7 | 0 | 0 |
鼻咽 | 2 | 0 | 1 | 1 | 0 |
乳腺 | 11 | 9 | 0 | 2 | 0 |
合计 | 90 | 67 | 12 | 9 | 2 |
诊断 | 例数 | CR | PR | MR | NR |
肺癌 | 74 | 10 | 33 | 25 | 6 |
食管癌 | 33 | 6 | 11 | 3 | 13 |
贲门癌 | 72 | 20 | 23 | 6 | 23 |
胃癌 | 21 | 9 | 4 | 2 | 6 |
直肠癌 | 1 | 0 | 0 | 1 | 0 |
膀胱癌 | 37 | 32 | 2 | 3 | 0 |
合计 | 238 | 77 | 73 | 40 | 48 |
年龄 | ~5 | ~10 | ~20 | ~30 | ~40 | >40 | 合计 |
男 | 12 | 10 | 34 | 34 | 2 | 2 | 94 |
女 | 25 | 26 | 33 | 42 | 16 | 2 | 144 |
共计 | 37 | 36 | 67 | 76 | 18 | 4 | 238 |
病变类型 | I完全效应 | II显著效应 | III中度效应 | IV无效 | 合计 |
鲜红型 | 4 | 8 | 9 | 0 | 21 |
粉红型 | 3 | 1 | 1 | 0 | 510 |
紫红型 | 12 | 63 | 93 | 2 | 170 |
增厚型 | 1 | 6 | 34 | 1 | 42 |
总计病例 | 20 | 78 | 137 | 3 | 238 |
百分比 | 8.4 | 32.8 | 57.6 | 1.2 | 10015 |
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005101345999A CN100368413C (zh) | 2005-12-20 | 2005-12-20 | 一种组成稳定的血卟啉衍生物及其制备方法和注射剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005101345999A CN100368413C (zh) | 2005-12-20 | 2005-12-20 | 一种组成稳定的血卟啉衍生物及其制备方法和注射剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1786001A true CN1786001A (zh) | 2006-06-14 |
CN100368413C CN100368413C (zh) | 2008-02-13 |
Family
ID=36783618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005101345999A Active CN100368413C (zh) | 2005-12-20 | 2005-12-20 | 一种组成稳定的血卟啉衍生物及其制备方法和注射剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100368413C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101467996B (zh) * | 2007-12-27 | 2012-05-09 | 上海复旦张江生物医药股份有限公司 | 次卟啉衍生物的用途 |
CN112675167A (zh) * | 2020-12-25 | 2021-04-20 | 范平生 | 一种血卟啉衍生物联合化学药物在乳腺癌治疗中的应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1130364C (zh) * | 2000-02-28 | 2003-12-10 | 上海复旦张江生物医药股份有限公司 | 次卟啉衍生物、其制备方法及注射用冻干制剂 |
-
2005
- 2005-12-20 CN CNB2005101345999A patent/CN100368413C/zh active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101467996B (zh) * | 2007-12-27 | 2012-05-09 | 上海复旦张江生物医药股份有限公司 | 次卟啉衍生物的用途 |
CN112675167A (zh) * | 2020-12-25 | 2021-04-20 | 范平生 | 一种血卟啉衍生物联合化学药物在乳腺癌治疗中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN100368413C (zh) | 2008-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1990484A (zh) | 水飞蓟宾酯类衍生物及其制备方法和用途 | |
CN1250294C (zh) | 光敏剂和及其生产方法 | |
CN1525857A (zh) | 用去甲二氢愈创木酸衍生物***的方法 | |
CN1090633C (zh) | 叶绿素a降解产物金属络合物、其制备方法及抗胃溃疡药物 | |
CN113956242A (zh) | 一种诱导免疫原性细胞死亡的光敏剂及其制备方法和应用 | |
CN113461740B (zh) | 一种铱配合物及其制备方法和应用 | |
CN1857529A (zh) | 一种***的注射用新藤黄酸制剂及其制备方法 | |
CN1786001A (zh) | 一种组成稳定的血卟啉衍生物及其制备方法和注射剂 | |
CN1305512C (zh) | 治疗乳腺增生的中药复方及其制备方法 | |
CN1686317A (zh) | 具有神经保护作用的银杏总内酯组合物 | |
CN1620305A (zh) | 诱导凋亡的方法和诱导凋亡的组合物 | |
CN1628662A (zh) | 具有镇痛作用的药物 | |
CN1219130A (zh) | 用于治疗眼部炎症的含硝酮化合物的组合物 | |
CN1174973C (zh) | 荆芥内酯及其提取工艺和用途 | |
CN1242999C (zh) | 苯并异硒唑衍生物及其应用 | |
CN1679648A (zh) | 脉络宁注射制剂及其制备方法和它的质量控制方法 | |
CN1291734C (zh) | 一种中药软胶囊制剂的质量控制方法 | |
CN1850202A (zh) | 一种***外用药物组合物及其制备方法和用途 | |
CN101077873A (zh) | 新的neo-克罗烷型二萜化合物及其应用 | |
CN1569867A (zh) | 山茱萸提取物莫诺苷的制备方法和用途 | |
CN1190394C (zh) | 菠萝叶提取物及其制备方法和用途 | |
CN1281238C (zh) | 治疗末梢神经炎的外用药及其制备方法 | |
CN1568943A (zh) | ***软膏及其制备方法和应用 | |
CN1665493A (zh) | 含有来自红豆杉的木聚糖类的降血糖剂、保肝药、抗癌剂 | |
CN1923191A (zh) | 二氢黄酮类化合物在制备治疗心血管疾病药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20060614 Assignee: Beijing Jiang Cheng Weiye Biological Technology Co., Ltd. Assignor: Huading Modern Biopharmaceutical Co., Ltd., Chongqing City Contract record no.: 2014990000217 Denomination of invention: Composition stable blood porphrin derivative, its preparation method and injection agent Granted publication date: 20080213 License type: Exclusive License Record date: 20140417 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
PP01 | Preservation of patent right |
Effective date of registration: 20140604 Granted publication date: 20080213 |
|
RINS | Preservation of patent right or utility model and its discharge | ||
PD01 | Discharge of preservation of patent |
Date of cancellation: 20141204 Granted publication date: 20080213 |
|
RINS | Preservation of patent right or utility model and its discharge | ||
PP01 | Preservation of patent right |
Effective date of registration: 20150316 Granted publication date: 20080213 |
|
RINS | Preservation of patent right or utility model and its discharge | ||
PD01 | Discharge of preservation of patent |
Date of cancellation: 20150916 Granted publication date: 20080213 |
|
PP01 | Preservation of patent right |
Effective date of registration: 20150916 Granted publication date: 20080213 |
|
RINS | Preservation of patent right or utility model and its discharge | ||
PD01 | Discharge of preservation of patent | ||
PD01 | Discharge of preservation of patent |
Date of cancellation: 20180713 Granted publication date: 20080213 Date of cancellation: 20180713 Granted publication date: 20080213 |
|
PP01 | Preservation of patent right | ||
PP01 | Preservation of patent right |
Effective date of registration: 20180713 Granted publication date: 20080213 Effective date of registration: 20180713 Granted publication date: 20080213 |
|
CP01 | Change in the name or title of a patent holder |
Address after: 401320 Dazhong Village, Yudong Town, Banan District, Chongqing Patentee after: Chongqing Maile Biopharmaceutical Co., Ltd. Address before: 401320 Dazhong Village, Yudong Town, Banan District, Chongqing Patentee before: Huading Modern Biopharmaceutical Co., Ltd., Chongqing City Address after: 401320 Dazhong Village, Yudong Town, Banan District, Chongqing Patentee after: Chongqing Maile Biopharmaceutical Co., Ltd. Address before: 401320 Dazhong Village, Yudong Town, Banan District, Chongqing Patentee before: Huading Modern Biopharmaceutical Co., Ltd., Chongqing City |
|
CP01 | Change in the name or title of a patent holder | ||
PD01 | Discharge of preservation of patent |
Date of cancellation: 20190113 Granted publication date: 20080213 Date of cancellation: 20190113 Granted publication date: 20080213 |
|
PD01 | Discharge of preservation of patent | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Composition stable blood porphrin derivative, its preparation method and injection agent Effective date of registration: 20200430 Granted publication date: 20080213 Pledgee: Tibet Huaxi Pharmaceutical Group Co., Ltd Pledgor: Chongqing Maile Biopharmaceutical Co., Ltd. Registration number: Y2020500000005 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Beijing Jiang Cheng Weiye Biological Technology Co., Ltd. Assignor: Huading Modern Biopharmaceutical Co., Ltd., Chongqing City Contract record no.: 2014990000217 Date of cancellation: 20200513 |